SEC Form 4 · accession 0001415889-16-006486
ACADIA PHARMACEUTICALS INC · ACAD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Glenn Baity
Officer — EVP AND GC
Period of report
Jul 11, 2016
Accepted (ET)
Jul 13, 2016 · 6:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001070494
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 11, 2016 | M | 4,057 | $6.78 | A | 66,978 | D | |
| Common StockF2 | Jul 11, 2016 | S | 4,057 | $35.0016 | D | 62,921 | D | |
| Common Stock | Jul 12, 2016 | M | 5,298 | $6.78 | A | 68,219 | D | |
| Common Stock | Jul 12, 2016 | M | 645 | $6.78 | A | 68,864 | D | |
| Common Stock | Jul 12, 2016 | M | 3,375 | $6.78 | A | 72,239 | D | |
| Common Stock | Jul 12, 2016 | M | 2,625 | $6.78 | A | 74,864 | D | |
| Common StockF3 | Jul 12, 2016 | S | 11,943 | $35.0022 | D | 62,921 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $6.78 | Jul 11, 2016 | M | 4,057 | D | — | Mar 7, 2017 | Common Stock | 4,057 | 5,298 | D |
| Stock Option (right to buy)F4 | $6.78 | Jul 12, 2016 | M | 5,298 | D | — | Mar 7, 2017 | Common Stock | 5,298 | 0 | D |
| Stock Option (right to buy)F4 | $6.78 | Jul 12, 2016 | M | 645 | D | — | Mar 7, 2017 | Common Stock | 645 | 0 | D |
| Stock Option (right to buy)F4 | $6.78 | Jul 12, 2016 | M | 3,375 | D | — | Mar 7, 2017 | Common Stock | 3,375 | 0 | D |
| Stock Option (right to buy)F4 | $6.78 | Jul 12, 2016 | M | 2,625 | D | — | Mar 7, 2017 | Common Stock | 2,625 | 0 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2015 and amended in May 2016.
- F2The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.04 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
- F3The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.03 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
- F425% of the shares subject to the Stock Option vested and became exercisable on March 8, 2008. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments.